#1 Clinical Trials Search in Europe

Tarlatamab

Tarlatamab, also known as AMG 757, is an innovative bispecific T-cell engager being studied in several clinical trials for the treatment of small cell lung cancer (SCLC) and other neuroendocrine tumors. This article explores the ongoing research into Tarlatamab’s efficacy, safety, and potential applications in various cancer types.

Table of Contents

What is Tarlatamab?

Tarlatamab, also known as AMG 757 or IMDELLTRA™, is a new and promising medication being developed to treat small cell lung cancer (SCLC)[1]. It belongs to a class of drugs called Bispecific T cell engagers (BiTE®), which are designed to help your immune system fight cancer more effectively[2].

This innovative drug is currently being studied in various clinical trials to determine its safety and effectiveness in treating SCLC, particularly in patients who have already tried other treatments without success[3].

How Tarlatamab Works

Tarlatamab works by targeting a specific protein called delta-like protein 3 (DLL3), which is found in high levels on small cell lung cancer cells[2]. The drug is designed to:

  • Attach to the DLL3 protein on cancer cells
  • Simultaneously connect to T cells, which are important immune cells in your body
  • Bring the T cells close to the cancer cells, allowing them to attack and destroy the cancer
This unique mechanism helps your immune system recognize and fight cancer cells more effectively, potentially leading to better treatment outcomes for patients with SCLC.

Conditions Treated by Tarlatamab

Tarlatamab is primarily being studied for the treatment of:

  • Small Cell Lung Cancer (SCLC): A fast-growing type of lung cancer that often spreads quickly to other parts of the body[1]
  • Extensive Stage Small Cell Lung Cancer: An advanced form of SCLC where the cancer has spread beyond one lung to other parts of the body[4]
  • Relapsed/Refractory Small Cell Lung Cancer: SCLC that has returned after initial treatment or has not responded to previous treatments[3]
Additionally, some research is exploring the potential use of Tarlatamab in treating neuroendocrine prostate cancer, a rare and aggressive form of prostate cancer[5].

Clinical Trials and Research

Tarlatamab is currently being studied in several clinical trials to evaluate its safety and effectiveness. Some key aspects of these trials include:

  • Phase 3 Studies: Large-scale trials comparing Tarlatamab to standard treatments for SCLC[6]
  • Combination Therapies: Studies exploring the use of Tarlatamab with other cancer treatments, such as immunotherapy drugs like Durvalumab[7]
  • Different Dosing Schedules: Researchers are investigating various ways to administer Tarlatamab to find the most effective and safe dosing regimen[2]
  • Expanded Access Programs: Some trials are designed to provide access to Tarlatamab for patients who have exhausted other treatment options[8]
These studies aim to determine how well Tarlatamab works in treating SCLC, its safety profile, and how it compares to existing treatments.

How Tarlatamab is Administered

Tarlatamab is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein[1]. The specific dosing schedule may vary depending on the clinical trial or treatment plan, but some common approaches include:

  • Every 2 weeks (Q2W) dosing[4]
  • Step-up dosing, where a lower dose is given initially, followed by higher doses in subsequent treatments[8]
  • Combination with other medications, such as immunotherapy drugs[7]
The duration of treatment and monitoring requirements may vary based on the specific study or treatment protocol.

Potential Side Effects

As with any medication, Tarlatamab may cause side effects. Researchers are closely monitoring patients in clinical trials to understand the safety profile of this drug. Some potential side effects being studied include:

  • Cytokine Release Syndrome (CRS): A condition where the immune system becomes overactive, potentially causing fever, chills, and other flu-like symptoms[2]
  • Infusion-related reactions: Symptoms that may occur during or shortly after receiving the IV infusion
  • Changes in laboratory test results: Such as blood cell counts or liver function tests[3]
It’s important to note that the full range of potential side effects is still being studied, and patients in clinical trials are closely monitored for any adverse reactions.

Future Prospects and Ongoing Research

The development of Tarlatamab represents an exciting advancement in the treatment of small cell lung cancer. Ongoing research is focused on:

  • Determining the most effective dosing regimens[9]
  • Exploring combination therapies with other cancer treatments[10]
  • Investigating the potential use of Tarlatamab in earlier stages of SCLC treatment[4]
  • Studying long-term outcomes and survival rates in patients treated with Tarlatamab[6]
As research progresses, Tarlatamab may become an important new option for patients with small cell lung cancer, potentially offering improved outcomes and quality of life for those affected by this challenging disease.

Aspect Details
Drug Name Tarlatamab (AMG 757, Imdelltra)
Drug Type Bispecific T-cell engager (BiTE)
Primary Indications Small Cell Lung Cancer (SCLC), other neuroendocrine tumors
Mechanism of Action Targets DLL3-expressing cancer cells and engages T cells
Administration Intravenous infusion, subcutaneous injection (in study)
Key Outcomes Measured Objective Response Rate (ORR), Duration of Response (DOR), Progression-Free Survival (PFS), Overall Survival (OS)
Safety Monitoring Treatment-emergent adverse events, vital signs, laboratory tests
Trial Phases Phase 1b, Phase 2, Phase 3b
Notable Features Step-up dosing regimen, exploration of different dose levels

FAQ

  • What is Tarlatamab? Tarlatamab is a bispecific T-cell engager designed to target DLL3-expressing cancer cells. It works by directing T cells in the body to attack cancer cells that express the DLL3 protein, which is found in high levels in small cell lung cancer and other neuroendocrine tumors.
  • What types of cancer is Tarlatamab being studied for? Tarlatamab is primarily being studied for small cell lung cancer (SCLC), but clinical trials are also investigating its use in other neuroendocrine tumors, extrapulmonary small cell carcinoma, neuroendocrine prostate cancer, and certain brain cancers with IDH mutations.
  • How is Tarlatamab administered? Tarlatamab is typically administered as an intravenous (IV) infusion. Some trials are exploring different dosing regimens, including a step-up approach with a lower initial dose followed by higher maintenance doses. There is also a study investigating subcutaneous administration.
  • What are the main outcomes being measured in Tarlatamab clinical trials? The main outcomes being measured include objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety profiles. Researchers are also looking at disease control rates and pharmacokinetic properties of the drug.
  • Are there any notable side effects of Tarlatamab? While specific side effects are not detailed in the trial summaries, the studies are closely monitoring for treatment-emergent adverse events, changes in vital signs, and laboratory test results. Some trials mention monitoring for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

Ongoing Clinical Trials on Tarlatamab

  • Study of Tarlatamab and Durvalumab compared to Durvalumab alone for patients with extensive stage small cell lung cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +10

  • Study of Tarlatamab alone or with FOLFIRI chemotherapy for patients with advanced digestive system or unknown origin neuroendocrine carcinomas

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

  • Study of Tarlatamab Treatment in Patients with Small Cell Lung Cancer: Evaluation of Different Dosing Schedules

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Italy Spain

  • Study of Tarlatamab Treatment for Patients with Small Cell Lung Cancer Who Have Not Responded to Two or More Previous Treatments

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Austria Belgium Denmark France Germany Greece +3

Glossary

  • Bispecific T-cell engager (BiTE): A type of immunotherapy that can bind to two different types of cells at the same time, typically a T cell and a cancer cell, to bring them together and activate the T cell to attack the cancer cell.
  • DLL3 (Delta-like protein 3): A protein that is highly expressed in small cell lung cancer and other neuroendocrine tumors, making it a target for cancer therapies like Tarlatamab.
  • Small Cell Lung Cancer (SCLC): An aggressive type of lung cancer that is often diagnosed at an advanced stage and has limited treatment options.
  • Neuroendocrine tumor: A type of cancer that begins in specialized cells called neuroendocrine cells, which have traits of both nerve cells and hormone-producing cells.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standard way to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a dose reduction.

References